ValenzaBio
Latest round
- Series A
Last raised
- Mar 2021
Total raised
- $79M
Investors
- 6
About ValenzaBio
Based in Maryland, US, ValenzaBio, Inc. was founded by co-founders Patrick Crutcher and David Maizenberg. Also in April 2021, Pierre Fabre Medicament takes an equity stake in the company. ValenzaBio contains a number of monoclonal antibodies that target surface antigens in order to decrease pathogenic autoreactive cell subpopulations, allowing researchers to develop novel therapeutic options for patients with autoimmune and inflammatory disorders by reducing harmful subpopulations of autoreactive cells. VB119, ValenzaBio's main program, is developed for the treatment of membranous nephropathy (MN), while VB421, for the treatment of thyroid eye disease. The company generates its revenue by providing treatment options for patients with autoimmune and inflammatory diseases. The company plans to advance and expand its pipeline towards clinical development, this includes VB119 and VB421.
Who invested in ValenzaBio
6 investors across 1 round
See all investors in ValenzaBio
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Mar 25, 2021
Amount
$79M
Investors
Questions about ValenzaBio
Who invested in ValenzaBio?
ValenzaBio has 6 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has ValenzaBio raised?
ValenzaBio has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did ValenzaBio last raise money?
ValenzaBio's most recent round on record is a Series A, in Mar 2021.
What does ValenzaBio do?
Based in Maryland, US, ValenzaBio, Inc.
Where is ValenzaBio headquartered?
ValenzaBio is headquartered in Bethesda, US.
Which VCs invest in companies like ValenzaBio?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at ValenzaBio's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like ValenzaBio? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.